Why the study?
Do NOACs reduce stroke, systemic embolism, bleeding, and mortality compared to warfarin in anticoagulation-naïve patients with atrial fibrillation?
Do NOACs reduce stroke, systemic embolism, bleeding, and mortality compared to warfarin in anticoagulation-naïve patients with atrial fibrillation?
In a real-world Swedish cohort, NOACs demonstrated similar stroke prevention efficacy to warfarin but with superior safety regarding major bleeding and mortality, supporting their use as preferred first-line therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Megaw et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: